Imbruvica Emerges as Winner in Treatment of CLL - Goldman Survey (PCYC) (ABBV) (GILD)
Tweet Send to a Friend
Goldman Sachs maintained a Buy rating on Pharmacyclics (NASDAQ: PCYC) and raised its price target to $174 (from $165). The ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
